Since its application in BRCA1/2-mutated cancer in a decade ago, synthetic lethality induced by PARPis has given renewed enthusiasm to developing anticancer treatments that can specifically target cancer cells but spare normal tissue 1,2 . Although different underlying mechanisms have been proposed 3, 4 , they are mostly attributed to critical functions of PARP in a variety of DNA-repair processes, including as a critical sensor of single-strand breaks (SSBs) in baseexcision repair (BER) 5, 6 ; as a mediator for restarting stalled replication forks of HR-mediated double-strand break (DSB) repair 7-9 ; and as a means of preventing the binding of Ku proteins to DNA ends in non-homologous end-joining (NHEJ) pathways 10 . Specifically, inhibition of BER impairs SSB repair, which results in accumulation of DSBs at the replication forks during the S phase of the cell cycle. DNA repair and survival of PARP-inhibited cells seem to be heavily dependent on HR, which is compromised in cancer cells carrying BRCA-related mutations [11] [12] [13] [14] [15] [16] [17] , leading to their unique susceptibility to PARPi treatment. There are also alternative but not mutually exclusive models in which PARPis may suppress transcriptional activity of PARP 1,18 and/or function as poisons that result in PARP-DNA complex trapping and selective killing 4 .
Since its application in BRCA1/2-mutated cancer in a decade ago, synthetic lethality induced by PARPis has given renewed enthusiasm to developing anticancer treatments that can specifically target cancer cells but spare normal tissue 1, 2 . Although different underlying mechanisms have been proposed 3, 4 , they are mostly attributed to critical functions of PARP in a variety of DNA-repair processes, including as a critical sensor of single-strand breaks (SSBs) in baseexcision repair (BER) 5, 6 ; as a mediator for restarting stalled replication forks of HR-mediated double-strand break (DSB) repair [7] [8] [9] ; and as a means of preventing the binding of Ku proteins to DNA ends in non-homologous end-joining (NHEJ) pathways 10 . Specifically, inhibition of BER impairs SSB repair, which results in accumulation of DSBs at the replication forks during the S phase of the cell cycle. DNA repair and survival of PARP-inhibited cells seem to be heavily dependent on HR, which is compromised in cancer cells carrying BRCA-related mutations [11] [12] [13] [14] [15] [16] [17] , leading to their unique susceptibility to PARPi treatment. There are also alternative but not mutually exclusive models in which PARPis may suppress transcriptional activity of PARP 1, 18 and/or function as poisons that result in PARP-DNA complex trapping and selective killing 4 .
In spite of its promise in breast and ovarian cancer, the clinical application of PARPis has not widely been translated to different cancers as an effective treatment, partly because mutations affecting DDR-associated genes are not common in other malignancies, including AML 19 , which is mainly driven by mutated transcription factors such as AML1-ETO, PML-RARα and MLL fusions 20 . The same chemotherapy that was developed more than half a century ago is still used for nearly all AML patients, with the only exception being acute promyelocytic leukemia (APL), which carries a PML-RARα fusion 21 . Owing to its high general toxicity, chemotherapy can usually only be applied to patients under age 60, leaving few or no treatment options for the majority of AML cases 21 . In addition, standard chemotherapy only induces less than 40% long-term complete remission and is mostly ineffective in patients carrying mutations in the KMT2A gene, which can be found in both AML and acute lymphoblastic leukemia (ALL) 21, 36 . Therefore there is an urgent need to develop better therapeutic strategies for AML. Because specific transcriptional programs, including those involved in DDR, are frequently deregulated by various oncogenic transcription factors, we reasoned that transcriptional deregulation might represent an alternative mechanism that would allow the use of synthetic lethality approaches for effective leukemia treatments 19 .
RESULTS

Inhibition of PARP suppresses leukemia driven by AML1-ETO and PML-RARa
To explore the therapeutic potentials of targeting PARP in acute leukemia, we investigated the effect of olaparib, a PARPi, on primary mouse hematopoietic cells transformed by the most common leukemia-associated transcription factors (LATFs), including 1 Leukemia and Stem Cell Biology Group, Department of Haematological Medicine, Division of Cancer Studies, King's College London, London, UK. 2 Cell Proliferation Group, Medical Research Council Clinical Sciences Centre, Imperial College London, London, UK. 3 Department of Medicine, The University of Hong Kong, Hong Kong, China. 4 University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. 5 AML1-ETO, PML-RARα, MLL-AF9 and E2A-PBX, using the retroviral transduction/transformation assay (RTTA) [22] [23] [24] [25] . Whereas a concentration of up to 1 µM olaparib exhibited minimal effects on normal bone marrow, it had a notable effect on transformed primary cells. PARPi significantly suppressed the colony-forming ability of cells transformed by AML1-ETO or PML-RARα by about 90%, although it exhibited little impact on MLL-AF9-or E2A-PBX-transformed cells (Fig. 1a,b and Supplementary Fig. 1a-d) . To confirm the specificity of the drug, we also reported very similar and selective leukemia-suppressive effects using a different PARPi, veliparib ( Supplementary  Fig. 1e,f) . To show that PARP1 was the major molecular target for the observed phenotype upon PARPi treatment, two independent Parp1-targeting shRNAs ( Supplementary Fig. 1g ,h) were used to deplete Parp1 in the RTTA. Consistently, both Parp1-targeting shRNAs significantly suppressed the colony-forming ability of cells transformed by AML1-ETO or PML-RARα, but not those transformed by E2A-PBX and MLL-AF9 (Fig. 1c,d and Supplementary Fig. 1i ).
To investigate the effects of PARPi on the corresponding human leukemias, we used patient-derived leukemic cell lines carrying AML1-ETO (Kasumi), mutated PML-RARα that is resistant to standard all-trans retinoic acid (ATRA) treatment (NB4-LR2) 25 , or MLL-AF9 (THP1) for the inhibitor studies. Analogously to the mouse models, PARPi reduced the colony-forming ability of Kasumi and NB4-LR2 cells, but not THP1 cells (Fig. 1e,f) . To further demonstrate potential in vivo efficacy, these cells were xenotransplanted into immunocompromised mice and subjected to the PARPi treatment. Despite being used as a monotherapy, olaparib significantly delayed the disease onset driven by AML1-ETO from a median survival of 55 d to 102 d (Fig. 1g, Supplementary Fig. 1j ,m, and Supplementary  Table 1) . Notably, olaparib as a single agent could also effectively suppress disease onset induced by ATRA-resistant APL cells (Fig. 1h,  Supplementary Fig. 1k ,n, and Supplementary Table 1 ). In contrast, PARPi had no effect on the survival of a xenograft mouse model transplanted with THP1 cells (Fig. 1i, Supplementary Fig. 1l ,o, and Supplementary Table 1) . To further substantiate these findings, we also observed very similar differential in vitro PARPi responses from primary AML patient samples carrying the corresponding translocation fusions (Supplementary Fig. 1p,q) . Together, these results reveal the potential therapeutic utility of PARPis in different subtypes of leukemia driven by specific LATFs, including AML1-ETO-driven leukemia and ATRA-resistant APL 26 .
PARPi treatment induces differentiation and senescence Although PARPi can generally slow leukemic cell growth, PARPi treatment of AML1-ETO-and PML-RARα-transformed mouse cells resulted in their morphological differentiation into monocytic and granulocytic lineages (Fig. 2a,b and Supplementary Fig. 2a-d) , which is consistent with recent observations of leukemic differentiation induced by excessive DNA damage 27 , suggesting that differential DDR may underlie the contrasting PARPi responses. PARPi treatment was also accompanied by cell cycle G1 arrest ( Fig. 2c and Supplementary  Fig. 2e ), upregulation of Tp53 (also known as p53), Cdkn1a (also known as p21) (Fig. 2d,e) and Cdkn2a (also known as p16) expression in AML1-ETO and PML-RARα-transformed cells (Fig. 2f) , which
Relative number of colonies 100 80 60 (Fig. 2g,h ). PARPi treatment also induced apoptosis of PML-RARα-transformed cells ( Fig. 2i and Supplementary Fig. 2f ). In contrast, none of these effects were observed in E2A-PBX-or MLL-AF9-transformed cells despite a small upward trend in differentiation and apoptosis ( Fig. 2a-i ). In accordance with the mouse data, PARPi could effectively induce senescence and apoptosis in Kasumi and NB4-LR2 cells but not THP1 cells ( Supplementary Fig. 2g-i) ; and increased differentiation of primary AML cells carrying AML1-ETO and PML-RARα fusions but not MLL fusions ( Supplementary Fig. 2j-l) . These results consistently suggest a specific requirement of PARP function in cells transformed by AML1-ETO and PML-RARα.
AML1-ETO-and PML-RARa-transformed cells show inherent DDR defects
Although the general rationale behind the PARPi sensitivity is a defect in DDR 3, 4, 15, 16, 28 , PARP also has transcriptional functions involved in gene regulation 1, 18 . After failing to detect direct biochemical interaction ( Supplementary Fig. 3a and M.T.E., T.K.F., N.M., J.G. and C.W.E.S., unpublished mass spectrometry data) and transcriptional regulation ( Supplementary Fig. 3b-e ) between PARP1 and any of the studied leukemia fusion proteins, we examined the kinetics of the DDR in primary transformed cells by analyzing Ser139-phosphorylated γH2AX foci, which are considered to be an early response to DSBs 29 . With the exception of E2A-PBX, untreated AML1-ETO-, PML-RARα-and MLL-AF9-transformed cells displayed significant levels of γH2AX DNA damage foci, indicative of ongoing DNA damage or replication stress (Fig. 3a,b and Supplementary Fig. 3f ). Upon PARPi treatment, both PARPi-insensitive and PARPi-sensitive cells showed further induction of γH2AX foci ( Fig. 3c and Supplementary  Fig. 3g-k) , suggesting that PARPi induced DNA damage regardless of the oncoprotein fusions. Then we investigated recruitment of the recombinase to DNA damage sites, as a readout of HR efficiency 30, 31 .
Upon PARPi treatment for 6 h, E2A-PBX or MLL-AF9 cells were able to efficiently form RAD51 foci, which then returned to basal levels after the repair in 24 h (Fig. 3c,d and Supplementary Fig. 3g-j,l) . In contrast, little RAD51 recruitment was observed in AML1-ETO or PML-RARα cells, in which around 80% showed γH2AX and RAD51 foci ratio greater than 2 ( Fig. 3e) , indicating their HR-deficient nature. The observed differential HR deficiency associated with PARPi treatment is unlikely to be due to different cell cycle status of these cells, as PARPi exhibited no significant effect on cell cycle progression in the first 24 h (Supplementary Fig. 3m ) when these assays were performed. To further extend our findings to human disease, we consistently observed higher levels of DNA damage in Kasumi and NB4-LR2 cells ( Supplementary Fig. 3n,o) , which also failed to effectively induce RAD51 foci upon PARPi treatment, as compared with THP1 cells (Supplementary Fig. 3p-r) . Next, we investigated and revealed a decreased expression of key HR genes including Rad51, Atm, Brca1 and Brca2 in both AML1-ETO 
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** ** * and PML-RARα mouse models (Fig. 3f) . By analyzing the expression array data of these genes in two different human AML cohorts 32,33 , we consistently observed very similar suppression of these HR mediators in human AML1-ETO-and PML-RARα−associated leukemia, as compared with MLL-rearranged leukemia (Fig. 3g, Supplementary  Fig. 3s and Supplementary Table 2) . We also further validated the protein expression of key HR mediators, RAD51 and BRCA2, using mouse primary leukemic cells transformed by the corresponding fusions (Fig. 3h) . To assess the direct effect of these fusions on DNA repair, we performed both a plasmid end-joining assay 34 and an HR reporter assay 35 . Nuclear extracts from E2A-PBX-and MLL-AF9-transformed cells could efficiently repair DSBs, and they produced significantly higher total numbers of colonies carrying the repaired plasmid than did AML1-ETO-and PML-RARα-transformed cells.
Moreover, in contrast to E2A-PBX-and MLL-AF9-transformed cells, most of the end repairs by nuclear extracts from AML1-ETO-or PML-RARα-transformed cells were mismatched (Fig. 3i) . Consistently, we also observed significant suppression of HR efficiency upon expression of AML1-ETO or PML-RARα, as opposed to a small and significant increase in HR upon expression of MLL-AF9 (Fig. 3j) . Therefore, these data indicate that leukemic cells driven by AML1-ETO and PML-RARα had a reduced ability to repair DSB and that the repairs were accompanied by an increased error rate, which may form the basis for their increased PARPi sensitivity.
Induction of HOXA9 by MLL fusions modulates PARPi sensitivity
In contrast to AML1-ETO and PML-RARα 20,24 , MLL-fusion proteins recruit transactivation complexes culminating in expression of . 20,36,37) , which was previously identified as one of the single most critical independent prognostic factors associated with poor AML treatment response 38 , and the suppression of which has been linked to the drug-resistant phenotype in glioblastoma 39, 40 . Consistently, we could observe specific and differential expression of Hoxa9 by MLL fusion in our mouse models and human samples ( Supplementary Fig. 4a-c) . Thus we hypothesized that the PARPi resistance exhibited by MLL-AF9-transformed cells might be dependent on the ability of MLL-AF9 to activate Hoxa9. To this end, we assessed the functional requirement of Hoxa9 in conferring PARPi resistance in MLL-AF9 cells using a Hoxa9-knockout mouse model. Consistent with previous reports 24, 41, 42 , knockout of Hoxa9 had a relatively modest effect on MLL-AF9-transformed cells despite a more mature phenotype and a slightly reduced colony-forming ability, as compared with their wild-type counterparts 41 ( Fig. 4a-c and Supplementary Fig. 4d-g ). Notably, ablation of Hoxa9 expression sensitized MLL-AF9-transformed cells, but not HOXA9-independent E2A-PBX-transformed control cells 24, 43 to PARPi treatment, which resulted in a significant suppression of colony-forming ability but inductions of differentiation and senescence (Fig. 4a-e and Supplementary Fig. 4d-f) . This is consistent with the role of Hoxa9 suppressing cellular senescence 24 , a common endpoint of excessive DNA damage. We then tested whether suppression of Hoxa9 sensitizes advanced-stage MLL leukemia to PARPi treatment in vivo by using MLL-AF9 full-blown leukemic cells harvested from primary transplanted mouse. As expected, olaparib did not have any significant effect on mice transplanted with wild-type MLL-AF9 leukemic cells. In contrast, although Hoxa9-deficient MLL-AF9 cells could efficiently induce leukemia, they were highly sensitive to PARPi treatment, which significantly delayed the disease latency (Fig. 4f,g and Supplementary Fig. 4h; Supplementary Tables 3 and 4 ). To further demonstrate the role of HOXA9 in mediating PARPi resistance, we also used a gain-of-function approach by overexpressing HOXA9 in PARPi-sensitive AML1-ETO-and PML-RARα-transformed cells. As expected, cells transduced with the vector control remained sensitive to PARPi. Forced expression of HOXA9 conferred PARPi resistance to AML1-ETO-and PML-RARα-transformed cells without affecting the expression of the fusions (Fig. 4h-j and Supplementary Fig. 4i,j) .
Together with the loss-of-function data, these results strongly suggest Hoxa9 as a key player in mediating PARPi resistance.
HOXA9 activates HR gene expression and DNA repair
Upon HOXA9 overexpression, we observed significant recruitment of RAD51 to DNA damage foci in AML1-ETO-and PML-RARα-but not E2A-PBX-or MLL-AF9-transformed cells, which already showed efficient recruitment of RAD51 (Fig. 5a-b) . Conversely, suppression of Hoxa9 expression resulted in a significant impairment of RAD51 recruitment in MLL-AF9 transformed cells (Fig. 5c-d) , leading to the hypothesis that HOXA9 might be an upstream regulator of RAD51. To this end, we analyzed the expression array data of known HOXA9 downstream targets in primary transformed myeloid cells 44, 45 . This revealed that genes involved in DNA repair were significantly enriched in HOXA9-responsive gene sets (Fig. 5e, Supplementary Fig. 5a ,b and Supplementary Table 2) , which was also confirmed by RT-qPCR using wild-type and Hoxa9-knockout MLL-AF9-transformed cells (Supplementary Fig. 5c ). Among them were key HR-related genes including Rad51 (refs. 12,30,31), a fact that was further validated in the primary transformed cells by both HOXA9 -overexpression (Fig. 5f) and Hoxa9-knockout approaches ( Fig. 5g and Supplementary Fig. 5d) . Consistently, the expression of RAD51 and BRCA2 proteins were significantly diminished in the absence of Hoxa9 (but not Ctnnb1 −/− control) (Fig. 5h) . Finally, to demonstrate a direct involvement of HOXA9 in DDR, HR-reporter assays further revealed enhanced HR efficiency by HOXA9 overexpression as opposite to a compromised HR response with HOXA9 suppression (Fig. 5i) . These data strongly suggest that HOXA9 confers PARPi-resistance in part by activating DDR transcriptional programs.
Targeting PARPi-resistant AML with a combination approach Although there is not yet a chemical inhibitor that can directly target HOXA9, inhibitors are available to suppress its regulators and essential co-factors, including GSK3, which mediates the phosphorylation of CREBBP (CREB binding protein, also known as CBP), which is required for HOX transcriptional functions 46 . We and others have previously shown that GSK3 inhibitors (GSKis), such as LiCl and Li 2 CO 3 , were effective in suppressing the transcriptional activity of HOXA9 and targeting MLL pre-leukemic stem cells (pre-LSCs), but not the advanced-stage MLL-LSCs that acquired resistance in part because of the activation of canonical Wnt/β-catenin pathways, and which were capable of inducing leukemia with a much shorter latency 23, 46, 47 . To further explore the potential application of PARPi on MLL leukemia, we assessed the effect of PARPi in combination with GSK3i, on both MLL pre-LSC-and MLL-LSC-enriched populations that exhibited contrasting GSKi sensitivity and disease latency 23 . As expected, the application of a previously-defined optimal concentration of LiCl (refs. 23,46,47) significantly suppressed the colony-forming ability of MLL pre-LSCs, but not MLL-LSCs (Fig. 6a,b and Supplementary  Fig. 6a-c) . Notably, combining LiCl with PARPi led to further inhibition of MLL pre-LSCs, which inversely correlated with transcriptional activity of HOXA9 as assessed by the expression of its downstream target, c-Myb (Fig. 6a-b) . Of further note, whereas individual PARPi or LiCl treatment was ineffective on MLL-LSCs, the combination of the two treatments dramatically suppressed growth and induced differentiation of MLL-LSCs (Fig. 6b-d ). To further demonstrate the in vivo efficacy, pretreated MLL-LSCs were transplanted into syngeneic mice and subjected to treatment with olaparib, Li 2 CO 3 , or the combination of the two. As expected, mice transplanted with control MLL-AF9 cells succumbed to leukemia within 8 weeks. PARPi or GSK3i treatment alone did not significantly extend the survival; notably, the combined PARPi and GSK3i treatment suppressed leukemia development, and all the mice survived throughout the experiment (Fig. 6e,  Supplementary Fig. 6d ,e, and Supplementary Table 5 ).
To investigate whether a similar treatment could also be effective in the corresponding human leukemia, we first used THP1 cells that were mostly refractory to olaparib and showed little effect when treated with LiCl. However in combination, LiCl could sensitize PARPiresistant THP1 cells to the PARPi treatment, resulting in significant growth suppression and differentiation (Supplementary Fig. 6f,g ). Then we performed the same treatments on two independent primary human AML samples carrying MLL-fusions (i.e., patient ID nos. AML1 and AML2). Whereas limited inhibition resulted from individual treatments, combination treatments showed consistent synergistic effects in suppressing growth and promoting differentiation of primary MLL leukemic cells from both patients (Fig. 6f-h) . Finally, to further demonstrate the in vivo treatment efficacy, we labeled cells from patient AML1 with a luciferase reporter prior to their transplantation into NSG mice for drug treatment. By in vivo imaging, we observed a rapid disease development as early as 4 weeks after transplant in the untreated control. We observed a similar rate of disease progression in cohorts receiving single-drug treatments, although the Li 2 CO 3 -treated group exhibited an even faster rate of leukemic growth ( Fig. 6i and Supplementary Fig. 6h ). In contrast, PARPi and Li 2 CO 3 combination treatment significantly prohibited leukemic growth in vivo (Fig. 6i and Supplementary  Fig. 6h ). After long-term disease development, mice that received single-drug treatments succumbed to leukemia with a similar phenotype and disease latency as the control group. Notably, the combination treatment significantly suppressed leukemia development, and none of the mice treated with combination therapy succumbed to leukemia throughout the observation period (Fig. 6j, Supplementary  Fig. 6i ,j and Supplementary Table 6 ). Together, these independent results from mouse and primary human xenograft models provide the first proof-of-principle pre-clinical evidence for a novel effective therapeutic strategy based on a combined PARPi and GSK3i treatment for MLL leukemia.
DISCUSSION
In spite of the lack of genetic mutations directly affecting DDR-associated genes, we provide molecular and preclinical data showing the potential utility of PARPi-mediated selective killing of leukemic cells carrying specific oncogenic transcription factors (Supplementary Fig. 7) . In addition to the discovery of strong PARPi sensitivity in leukemic cells driven by AML1-ETO and PML-RARα, which suppress DDR [48] [49] [50] [51] [52] , we also demonstrate for the first time that HOXA9, an independent poor prognostic factor in AML 38 and a key downstream target of MLL-fusions 53 , can activate DDR pathways and allow leukemia cells to overcome PARPis. This finding may also in part explain the previously reported S-phase checkpoint dysfunction of MLL-rearranged cells that show radio-resistant DNA synthesis and chromatid-type genomic abnormalities 54 . Emerging evidence suggests that various HOX proteins may be involved in DNA repair 55, 56 . HOXB7 interacts with PARP-1 and the DNA-PK-Ku80-Ku70 complex-enabling NHEJ pathway 55 , whereas HOXB9 promotes HR by inducing TGF-β, which in turn enhances ataxia telangiectasia-mutated (ATM) activation and ATM-dependent response in breast cancer cell lines 56 . Our data indicate that HOXA9 mediates expression of critical DDR-related genes to stimulate an HR response to PARPi treatment. Consistent with its putative role in mediating drug-resistance in glioma 43, 44 , we further demonstrate that HOXA9 overexpression rescues AML1-ETO-and PML-RARα-transformed cells from PARPi treatment, whereas HOXA9 suppression makes MLL-AF9-transformed cells sensitive to PARPi, revealing a novel function of HOXA9 in governing PARPi resistance in AML.
In line with a classical model of DDR barrier in cancer development 57 , a recent study by Takacova et al. 58 demonstrated that inactivation of the DDR barrier through ATM and ataxia telangiectasia and Rad3-related (ATR) inhibitors accelerated leukemia driven by a tamoxifen-inducible MLL-fusion 58 . In contrast, Santos et al. 59 have elegantly shown that genetic ablation of critical DDR-associated npg genes such as MLL4, ATM or BRCA1, instead of accelerating MLLdriven leukemogenesis, induced leukemic differentiation. These results suggest dual roles of the key DDR players, such as ATM, in promoting and suppressing MLL-leukemia, which may be dosage and context dependent. Notably, HOXA9, which drives leukemic growth and PARPi resistance, is largely dispensable for normal development 24, 42, 60 , highlighting its potential as a therapeutic target. As a proof of principle, we further demonstrate that the combined use of PARPi together with GSK3i, which targets the transcriptional function of HOXA9 (refs. 23,46,47) , can achieve selective killing of otherwise PARPi-resistant MLL leukemia, revealing a novel venue for overcoming PARPi resistance in leukemia (Supplementary Fig. 7) .
METHODS
Methods and any associated references are available in the online version of the paper. at 4 °C overnight with the primary antibody (Supplementary Table 7) . After four washes with TBS-T, the membrane was incubated for 1 h with the horseradish peroxidase (HPR)-conjugated antibody, anti-mouse or anti-rabbit (Jackson ImmunoResearch) diluted in blocking buffer. Antibody binding was visualized using the ECL Prime western blotting detection system (GE Healthcare).
Immunoprecipitation assay. Cells were lysed as above (with a reduced NaCl concentration to 200 mM). The 500 µg of total cell lysates were incubated with 1 µg anti-FLAG antibody at 4 °C for 12 h with rotation. Then protein A-conjugated beads were added to precipitate the protein complex and incubated at 4 °C for 1 h with rotation. Beads were then washed five times with reduced NaCl cell lysis buffer and eluted with 50 µl of 2% SDS-Tris buffer.
Real time Quantitative PCR. RNA was extracted by using a kit from Fermentas and was reverse transcribed using SuperScript III from Invitrogen. qPCR was performed by using SYBR Green or Taqman probes on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems) using primers (Supplementary Table 8 ). Gapdh was used a housekeeping gene. Relative expression levels were calculated using the 2 -∆∆CT method (ref. 64 ).
In vivo plasmid end-joining assay. The in vivo plasmid end-joining assay was performed as described 65 . Briefly, a DSB is generated in the lacZ gene sequence of the plasmid PUC18 by EcoRI digestion. Nuclear extracts from pre-leukemic cells carrying the above-mentioned fusion oncoproteins were obtained by using the Nuclear Extraction Kit (Pierce). 2 µg of PUC18 plasmid was digested with EcoRI (Fermentas), dephosphorylated (Fermentas), separated on a 1% agarose gel and extracted using a column-based method (Qiagen). 5 µg of nuclear extracts were then incubated in NHEJ buffer (50 mM triethanolammine HCl pH7.5, 60 mM potassium acetate, 0.5 mM magnesium acetate, 250 µM dNTPs, 10 mM ATP, 5 mM dTT, 500 µg/ml BSA) for 5 min at 37 °C. 250 ng of digested dephosphorylated plasmid were then added to the reaction in 50-100µl final volume and incubated for 24 h at 18 °C. The next day, the DNA was purified using a column-based method (Qiagen) and 30 ng were used to transform Escherichia coli and plate them on LB-agar plates + 160 µg/ml X-Gal (Sigma-Aldrich) and 1 mM IPTG (SigmaAldrich). Colonies were counted and plotted. The percentage of misrepair was calculated as the percentage of blue colonies versus the total number of colonies. In vivo experiments. All the experimental procedures were approved by the King's College London Animal Welfare and Ethical Review Body and conform to the UK Home Office regulations. For all in vivo experiments, mice were distributed into their respective groups randomly. Investigators were not blinded to the sample identity. Mice were considered leukemic when an engraftment of donor cell was detected.
We established humanized models of AML1-ETO and PML-RARα leukemia in sub-lethally irradiated NOD/SCID/IL2Rg −/− (NSG, 1 dose 200 RADs) by transplanting 2 × 10 6 Kasumi (intrafemoral, i.f.) and 10 5 NB4-LR2 or 10 5 THP1 (intravenous, i.v.) cells. The day after the transplantation, mice were split into two groups with an equal number of males and females in each group and given intraperitoneal injections of vehicle (10% HBC) or olaparib (25 mg/kg in 10% HBC) daily for 2-4 weeks. The maximum tolerable dose was calculated by in vivo dose-response experiments. Mice were monitored daily until they developed symptoms of leukemia, when they were culled, and bone marrow, spleen and liver was harvested and analyzed by FACS. The engraftment of human donor cells was defined as CD45 + CD33 + double-positive by FACS.
For Hoxa9-knockout studies, we intravenously injected 10 6 MLL-AF9 leukemic cells (wild type or Hoxa9 −/− background) together with 2 × 10 5 bone marrow rescue cells into lethally irradiated female C57Bl/6 mice (2 doses of irradiation, 550 rads each). For drug studies, the control cohort received vehicle (10% 2-hydroxpropyl-beta-cyclodextrin, HBC, Sigma-Aldrich) and the PARPi treatment group received daily olaparib 50 mg/kg in 10% HBC for 2-4 weeks.
For mouse MLL-AF9 LSC in vivo studies involving PARPi and GSK3i, MLL-AF9 LSCs were pretreated in R20/20 with 4 mM LiCl or 1 µM olaparib or a combination thereof for 3 d. Equal number 0.2 × 10 6 of live cells were transplanted into sublethally irradiated C57Bl/6 female mice. Continuous olaparib and Li 2 CO 3 treatment was commenced on the day after irradiation and injection of cells. Mice were given 0.4% lithium carbonate-containing diet (Harlan Laboratory) along with olaparib by intraperitonal injection every other day for 4 weeks. The engraftment of mouse donor cells was defined as CD45.1 + CD45.2 − by FACS.
For in vivo experiments with primary AML samples, 10 5 patient-derived leukemic cells carrying MLL rearrangement (AML1) transduced with a firefly luciferase-expressing plasmid were transplanted via by i.f. injection into the right femur of the NSG mice. Three days after transplantation, mice were supplemented with 0.4% Li 2 CO 3 -containing diet and treated with olaparib as described above for alternative day until day 21. After day 21, mice were maintained on 5 d of Li 2 CO 3 diet and alternated with 2 d of regular diet and water for 2 additional weeks. From day 21, the tumor burdens of the animals were detected using IVIS Lumina II (Caliper) with Living Image version 4.3.1 software (PerkinElmer). Briefly, 100 µl of 30 mg/ml luciferin was injected into the animals intraperitoneally 10 min after injection, the animals were maintained in general anaesthesia by isoflurane and put into the IVIS chamber for photography and detection of photon emission (large binning, F = 1.2, exposure time: 3 min). The tumor burdens were measured and quantified by the same software. The animals were culled when the tumor burden was 10 8 photons per second or higher.
Microarray and bioinformatic analysis. Expression profiles of AML1-ETO (22 samples, cluster 13), APL (18 samples, cluster 12), MLL (11 samples, cluster 16) patients were obtained from GEO accession: GSE1159 (ref. 32) . The data was supported by performing additional gene expression analysis on an independent set of published microarray data set from GSE6891 containing AML1-ETO (37 samples), APL (25 samples), and MLL (35 samples) leukemia samples. All intensity values was adjusted, normalized and summarized in log 2 scale using Bioconductor Affy 66 (background correction: rma; normalization: quantiles; summarization: median polish). The differential expression analyses on patients with leukemia exhibiting AML1-ETO and APL (PML-RARα) against MLL were performed using Bioconductor (http://www.bioconductor.org/) with limma. P values were calculated by paired two-tailed t-test. The expression of key genes involved in DNA repair (Supplementary Table 2 ) from patients with leukemia expressing AML-ETO, APL (PML-RARα) and MLL fusions was plotted in box-whisker plot using Prism5 software. GSEA was performed as described 67 using published data sets 44, 45 .
Statistical analyses. All the experimental results were analyzed using unpaired two-tailed Student's t-test, one-way or two-way ANOVA, as indicated in figure legends. Groups that were statistically compared shared a similar variance, as shown in the figures. P < 0.05 was considered statistically significant. The log-rank test was used to compare survival curves.
